Evidence map›Paper›PMID 15956591›Full record

ArticleJournal of virology2005

DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Margherita Rosati, Agneta von Gegerfelt, Patricia Roth, Candido Alicea, Antonio Valentin, Marjorie Robert-Guroff, David Venzon, David C Montefiori, Phil Markham, Barbara K Felber and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 94 citations in OpenAlex.

  1. Trial
  2. Recent advances in CD8Heliyon · 2023
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Vaccine protection against SIVmac239 acquisition.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  12. Article
  13. Journal of virology · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Margherita RosatiHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, Bldg. 535, Rm. 210, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA.
Agneta von Gegerfelt
Patricia Roth
Candido Alicea
Antonio Valentin
Marjorie Robert-Guroff
David Venzon
David C Montefiori
Phil Markham
Barbara K Felber
George N Pavlakis
National Cancer Institute · USBioScience Laboratories (United States) · USDuke Medical Center · US

Funding

Prevention of AIDSZIABC010350 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2009 to 2025
$30.0M
Immunotherapeutic Approaches for AIDSZIABC010749 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2009 to 2022
$21.6M
HUMORAL AND CELLULAR IMMUNE RESPONSES TO HUMAN AND NONHUMAN PRIMATE RETROVIRUSESZ01BC005536 · NCI · BASIC SCIENCES · PI ROBERT-GUROFF, MARJORIE · 1996 to 2007
$4.1M
Prevention of AIDSZ01BC010350 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2000 to 2008
$3.2M
DNA VaccinesZ01BC010749 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2006 to 2008
$1.7M
HIV Molecular Biology /DNA Vaccine Approaches to AIDSZ01SC010387 · SC · CLINICAL SCIENCES · PI PAVLAKIS, GEORGE N. · 2001 to 2005
–
6 · The paper itself

Abstract

We have tested the efficacy of DNA immunization as a single vaccination modality for rhesus macaques followed by highly pathogenic SIVmac251 challenge. To further improve immunogenicity of the native proteins, we generated expression vectors producing fusion of the proteins Gag and Env to the secreted chemokine MCP3, targeting the viral proteins to the secretory pathway and to a beta-catenin (CATE) peptide, targeting the viral proteins to the intracellular degradation pathway. Macaques immunized with vectors expressing the MCP3-tagged fusion proteins developed stronger antibody responses. Following mucosal challenge with pathogenic SIVmac251, the vaccinated animals showed a statistically significant decrease in viral load (P = 0.010). Interestingly, macaques immunized with a combination of vectors expressing three forms of antigens (native protein and MCP3 and CATE fusion proteins) showed the strongest decrease in viral load (P = 0.0059). Postchallenge enzyme-linked immunospot values for Gag and Env as well as gag-specific T-helper responses correlated with control of viremia. Our data show that the combinations of DNA vaccines producing native and modified forms of antigens elicit more balanced immune responses able to significantly reduce viremia for a long period (8 months) following pathogenic challenge with SIVmac251.

Indexed as

AIDS VaccinesVaccines, DNAAnimalsAntibodies, ViralCell LineHIV AntigensHumansLymphocyte ActivationMacaca mulattaSimian Immunodeficiency VirusViremiaAIDS VaccinesAntibodies, ViralHIV AntigensVaccines, DNA

Identifiers

PMID15956591
PMCPMC1143718
OpenAlexW2124974937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.